



Figure S1. Directed acyclic graph representing causal dependencies among study variables, exposures and outcome(s).

Table S1. Characteristics of other previous cART regimens performed by experienced participants.

Other prior cART (N=68)	N°	%
PI-boosted	14	20.6%
NRTI/INSTI/PI-boosted	13	19.1%
NRTI/NNRTI/INSTI/PI-boosted	10	14.7%
NRTI/NNRTI/PI-boosted	8	11.8%
INSTI/PI-boosted	7	10.3%
NRTI	5	7.3%
NNRTI/PI-boosted	3	4.4%
Other	8	11.8%

Table S2. Characteristics of experienced participants.

Characteristics of experienced participants (N=300)	N° or Median	% or (IQR)
Age (years)	54	(47-58)
Female sex	77	25.7%
Country (Italy)	255	85.0%
Year of starting DTG		
2018	19	6.3%
2019	239	79.7%
2020	39	13.0%
2021	3	1.0%
cART backbone		
XTC/TFX	38	12.7%
3TC	96	32.0%
XTC/ABC	113	37.7%
RPV	35	11.7%
DRV/RTV	18	6.0%
Mode of transmission		
Other	21	7.0%
MSM	79	26.3%
IDU	78	26.0%
Heterosexual	122	40.7%
HBsAg chronic carriers	7	2.3%
Positive HCV Ab participants	89	29.7%
Prior/baseline cancer	24	8.0%
Baseline HIV RNA Log₁₀ copies/mL	1.7	(1.7-1.7)
Baseline CD4 T-cells/mm³	700	(536-897)
Baseline CD8 T-cells/mm³	808	(589-1114)
Baseline CD4/CD8 ratio	0.83	(0.59-1.18)
Baseline FIB-4 score	1.08	(0.76-1.55)
Baseline eGFR (ml/min)	90.38	(76.27-101.87)
Baseline Framingham score	13	(10-15)
Death	1	0.3%
Total follow up time (days)	597.5	(360.75-744)

Table S3. Characteristics of naïve participants.

Characteristics of naïve participants (N=71)	N° or Median	% or (IQR)
Age (years)	48	(39-55)
Female sex	15	21.1%
Country (Italy)	54	76.1%
Year of starting DTG		
2018	2	2.8%
2019	58	81.7%
2020	3	4.2%
2021	8	11.3%
cART backbone		
XTC/TFX	42	59.2%
3TC	10	14.1%
XTC/ABC	16	22.5%
RPV	1	1.4%
DRV/RTV	2	2.8%
Mode of transmission		
Other	4	5.6%
MSM	23	32.4%
IDU	2	2.8%
Heterosexual	42	59.2%
HBsAg chronic carriers	0	0.0%
Positive HCV Ab participants	6	8.5%
Prior/baseline cancer	9	12.7%
Baseline HIV RNA Log₁₀ copies/mL	5.05	(4.4-5.38)
Baseline CD4 T-cells/mm³	207	(54-463)
Baseline CD8 T-cells/mm³	805	(486-1092)
Baseline CD4/CD8 ratio	0.18	(0.09-0.52)
Baseline FIB-4 score	1.01	(0.62-1.54)
Baseline eGFR (ml/min)	100.3	(86.38-109.41)
Baseline Framingham score	9	(4-12)
Death	0	0.0%
Total follow up time (days)	363	(252-645)